- AU$297.42m
- AU$245.87m
- $43.43m
- 95
- 45
- 98
- 92
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.9 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -1.79% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.39 | ||
| Price to Tang. Book | 5.66 | ||
| Price to Free Cashflow | 20.83 | ||
| Price to Sales | 4.12 | ||
| EV to EBITDA | 12.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.33% | ||
| Return on Equity | 17.87% | ||
| Operating Margin | 21.67% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.78 | 32.7 | 45.03 | 40.45 | 43.43 | 51.2 | 52.72 | 14.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +40.64 | -52.43 | +55.61 | +60.25 | -2 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Directors
- Martyn Myer NEC
- Brad O'Connor CEO
- Darren Watson CFO
- Frank Cheng CEX (48)
- Ben Bloomfield CTO
- Chris Edgar CSO
- Kenneth Billard OTH
- Sophie Egholm OTH
- Paul Maruff OTH
- Abby Moore OTH
- Jason Sada OTH
- David Franks SEC
- David Dolby NED (43)
- Richard Mohs NED
- Ingrid Player NID
- Richard van den Broek NID (55)
- Kim Wenn NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 17th, 1999
- Public Since
- February 13th, 2004
- No. of Shareholders
- 2,022
- No. of Employees
- 61
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 171,919,519
- Address
- Level 32, 367 Collins Street, MELBOURNE, 3000
- Web
- https://cogstate.com/
- Phone
- +61 396641300
- Contact
- David Franks
- Auditors
- Pitcher Partners
Upcoming Events for CGS
Full Year 2025 CogState Ltd Earnings Release
CogState Ltd Annual Shareholders Meeting
CogState Ltd Annual Shareholders Meeting
CogState Ltd Shareholder Day
Similar to CGS
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Cogstate share price?
As of Today at 20:01 UTC, shares in Cogstate are trading at AU$1.73. This share price information is delayed by 15 minutes.
How has the Cogstate share price performed this year?
Shares in Cogstate last closed at AU$1.73 and the price had moved by +54.46% over the past 365 days. In terms of relative price strength the Cogstate share price has outperformed the ASX All Ordinaries Index by +41.38% over the past year.
What are the analyst and broker recommendations for Cogstate?
The overall consensus recommendation for Cogstate is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cogstate dividend yield?
Cogstate does not currently pay a dividend.
Does Cogstate pay a dividend?
Cogstate does not currently pay a dividend.
When does Cogstate next pay dividends?
Cogstate does not currently pay a dividend.
How do I buy Cogstate shares?
To buy shares in Cogstate you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cogstate?
As of the previous close price of AU$1.73, shares in Cogstate had a market capitalisation of AU$297.42m.
Where are Cogstate shares listed?
Here are the trading details for Cogstate:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CGS
What kind of share is Cogstate?
Based on an overall assessment of its quality, value and momentum Cogstate is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cogstate share price forecast for 2025?
The analyst consensus target price for shares in Cogstate is AU$1.83. That is 6.05% above the last closing price of AU$1.73.
Analysts covering Cogstate currently have a consensus Earnings Per Share (EPS) forecast of $0.05 for the next financial year.
Find out moreWhat is the trend in the Cogstate share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cogstate. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +61.63%.
As of the last closing price of AU$1.73, shares in Cogstate were trading +45.97% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cogstate PE Ratio?
The Cogstate PE ratio based on its reported earnings over the past 12 months is 22.9. The shares last closed at AU$1.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cogstate?
Cogstate's management team is headed by:
- Martyn Myer - NEC
- Brad O'Connor - CEO
- Darren Watson - CFO
- Frank Cheng - CEX
- Ben Bloomfield - CTO
- Chris Edgar - CSO
- Kenneth Billard - OTH
- Sophie Egholm - OTH
- Paul Maruff - OTH
- Abby Moore - OTH
- Jason Sada - OTH
- David Franks - SEC
- David Dolby - NED
- Richard Mohs - NED
- Ingrid Player - NID
- Richard van den Broek - NID
- Kim Wenn - NID